ME Therapeutics Holdings Inc.
METXF
$2.95
$0.000.09%
OTC PK
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 29.98% | -40.26% | |||
| Depreciation & Amortization | -3.86% | 8.95% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.29% | -11.18% | |||
| Operating Income | -30.29% | 11.18% | |||
| Income Before Tax | -36.26% | 16.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -36.26% | 16.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -36.26% | 16.46% | |||
| EBIT | -30.29% | 11.18% | |||
| EBITDA | -31.97% | 12.09% | |||
| EPS Basic | -35.21% | 16.47% | |||
| Normalized Basic EPS | -36.36% | 16.98% | |||
| EPS Diluted | -31.51% | 14.12% | |||
| Normalized Diluted EPS | -36.36% | 16.98% | |||
| Average Basic Shares Outstanding | 0.00% | 0.87% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||